title: [Childhood tuberculosis].
abstract: Childhood TB is an indication of failing TB control in the community. It allows disease persistence in the population. Mortality and morbidity due to TB is high in children. Moreover, HIV co-infection and multidrug-resistant diseases are as frequent in children as in adults. Infection is more frequent in younger children. Disease risk after primary infection is greatest in infants younger than 2 years. In case of exposure, evidence of infection can be obtained using the tuberculin skin test (TST) or an interferon-gamma assay (IGRA). There is no evidence to support the use of IGRA over TST in young children. TB suspicion should be confirmed whenever possible, using new available tools, particularly in case of pulmonary and lymph node TB. Induced sputum, nasopharyngeal aspiration and fine needle aspiration biopsy provide a rapid and definitive diagnosis of mycobacterial infection in a large proportion of patients. Analysis of paediatric samples revealed higher sensitivity and specificity values of molecular techniques in comparison with the ones originated from adults. Children require higher drugs dosages than adults. Short courses of steroids are associated with TB treatment in case of respiratory distress, bronchoscopic desobstruction is proposed for severe airways involvement and antiretroviral therapy is mandatory in case of HIV infection. Post-exposure prophylaxis in children is a highly effective strategy to reduce the risk of TB disease. The optimal therapy for treatment of latent infection with a presumably multidrug-resistant Mycobacterium tuberculosis strain is currently not known.
authors.affiliation: Pavillon B, hôpital Abderrahmen-Mami, 2080 Ariana, Tunisie. Electronic address: agnes.hamzaoui@rns.tn.
authors.forename: A
authors.initials: A
authors.lastname: Hamzaoui
mesh_terms: D000293:Adolescent; D000995:Antitubercular Agents / Q000627:therapeutic use; D044963:Biopsy, Fine-Needle; D002648:Child; D002675:Child, Preschool; D014943:Global Health; D015658:HIV Infections / Q000150:complications; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D059425:Interferon-gamma Release Tests; D008403:Mass Screening; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D011237:Predictive Value of Tests; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome; D014374:Tuberculin Test / Q000379:methods; D014376:Tuberculosis / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000517:prevention & control; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000517:prevention & control
chemical_list: D000995:Antitubercular Agents
keywords: BCG; BCG vaccine; Childhood; Enfant; Interferon-gamma release test; Latent tuberculosis; Test de production de l’interféron gamma; Traitement; Treatment; Tuberculose; Tuberculose latente; Tuberculosis